SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001683168-22-007821
Filing Date
2022-11-16
Accepted
2022-11-16 17:00:16
Documents
14
Period of Report
2022-11-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT phio_8k.htm   iXBRL 8-K 35893
2 CERTIFICATE OF DESIGNATION OF SERIES D PREFERRED STOCK, DATED NOVEMBER 16, 2022 phio_ex0301.htm EX-3.1 20484
3 SUBSCRIPTION AND INVESTMENT REPRESENTATION AGREEMENT phio_ex1001.htm EX-10.1 38304
  Complete submission text file 0001683168-22-007821.txt   285934

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE phio-20221116.xsd EX-101.SCH 3233
5 XBRL LABEL FILE phio-20221116_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE phio-20221116_pre.xml EX-101.PRE 22363
8 EXTRACTED XBRL INSTANCE DOCUMENT phio_8k_htm.xml XML 3715
Mailing Address 257 SIMARANO DRIVE SUITE 101 MARLBOROUGH MA 01752
Business Address 257 SIMARANO DRIVE SUITE 101 MARLBOROUGH MA 01752 (508) 767-3861
Phio Pharmaceuticals Corp. (Filer) CIK: 0001533040 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36304 | Film No.: 221395968
SIC: 2834 Pharmaceutical Preparations